← IndicationsOpen filtered programs
Landscape
Noise-Induced Hearing Loss
Noise-Induced Hearing Loss has 23 tracked records across 12 named organizations, including 2 strong-evidence records and 6 active programs. Records with caveats and trial-derived candidates remain visible for deeper review.
23
Pipeline Records
strong evidence + caveats + candidates
2
Strong Evidence
21 checked records with caveats
6
Active Programs
currently active
2
Marketed / Approved
commercial or approved
12
Organizations
companies, sponsors, and institutions
Competitive Density
39/100
organization breadth + program volume
Pipeline Velocity
25/100
active and late-stage share
Evidence Coverage
9/100
share strong evidence
Completion Signal
30/100
late-stage, approved, or marketed
Attrition Rate
22/100
share discontinued
Concentration
52/100
top-organization share
Programs by Stage
Preclinical2 · 9%
Phase 12 · 9%
Phase 1/23 · 13%
Phase 27 · 30%
Phase 32 · 9%
Marketed3 · 13%
Not applicable4 · 17%
Trial / Program Status
Active6 · 26%
Marketed2 · 9%
Completed8 · 35%
Discontinued5 · 22%
Unknown2 · 9%
Modality Breakdown
Small Molecule12 · 52%
Regenerative Medicine4 · 17%
Diagnostic3 · 13%
Audiology/Diagnostic Assessment1 · 4%
Biologic1 · 4%
Drug Delivery1 · 4%
Electrophysiology/Diagnostic Assessment1 · 4%
Program Types
Therapeutic18 · 78%
Diagnostic5 · 22%
Top Organizations
Institution-led study12 · 52%
Boehringer Ingelheim1 · 4%
Edison Pharmaceuticals Inc.1 · 4%
Frequency Therapeutics1 · 4%
hearX1 · 4%
Institution-led study cluster1 · 4%
Otologic Pharmaceutics1 · 4%
Otonomy1 · 4%
Population Tags
adult23 · 100%
noise-induced20 · 87%
tinnitus7 · 30%
age-related5 · 22%
healthy-volunteer3 · 13%
cisplatin-ototoxicity2 · 9%
otoprotection2 · 9%
repurposed-drug2 · 9%
sensorineural2 · 9%
study-level2 · 9%
Strong-Evidence Programs
2 recordsChecked Records With Caveats
21 recordsFX-322 by Frequency Therapeutics
Company: Frequency Therapeutics · Phase 2 · Discontinued
Regenerative MedicinePhase 2Discontinued96% confidence
NHPN-1010
Company: Otologic Pharmaceutics · Phase 1 · Completed
Small MoleculePhase 1Completed89% confidence
hearX hearTest
Company: hearX · Marketed · Marketed
DiagnosticMarketedMarketed90% confidence
SHOEBOX PureTest
Company: SHOEBOX · Marketed · Marketed
DiagnosticMarketedMarketed88% confidence
OTO-6XX by Otonomy
Company: Otonomy · Preclinical · Discontinued
Regenerative MedicinePreclinicalDiscontinued84% confidence
WHO hearWHO Hearing ScreenerStatus caveat
Sponsor / Institution: World Health Organization · Marketed · Active
DiagnosticMarketedActive88% confidence
National Taiwan University NAC Noise-Induced Hearing Loss StudyStatus caveat
Sponsor / Institution: Institution-led study · Phase 2 · Completed
Small MoleculePhase 2Completed88% confidence
Electrocochleography hearing-study clusterStatus caveat
Sponsor / Institution: Institution-led study cluster · Not applicable · Completed
Electrophysiology/Diagnostic AssessmentNot applicableCompleted87% confidence
University of Michigan Soundbites micronutrient NIHL prevention studyStatus caveat
Sponsor / Institution: Institution-led study · Phase 2 · Completed
Small MoleculePhase 2Completed86% confidence
Gabapentin tinnitus study clusterStatus caveat
Sponsor / Institution: Institution-led study · Phase 2 · Completed
Small MoleculePhase 2Completed86% confidence
Zinc gluconate tinnitus and noise-induced hearing-loss studyStatus caveat
Sponsor / Institution: Institution-led study · Not applicable · Completed
Small MoleculeNot applicableCompleted86% confidence
Antioxidant prevention study for noise-induced hearing loss and tinnitusStatus caveat
Sponsor / Institution: Institution-led study · Not applicable · Unknown
Small MoleculeNot applicableUnknown84% confidence
Southern Illinois D-Methionine Noise-Induced Hearing Loss StudyStatus caveat
Sponsor / Institution: Institution-led study · Phase 3 · Discontinued
Small MoleculePhase 3Discontinued84% confidence
EPI-743 by Edison Pharmaceuticals for noise-induced hearing lossStatus caveat
Company: Edison Pharmaceuticals Inc. · Phase 2 · Completed
Small MoleculePhase 2Completed84% confidence
Acute acoustic trauma speech-in-noise assessment studyStatus caveat
Sponsor / Institution: Institution-led study · Not applicable · Unknown
Audiology/Diagnostic AssessmentNot applicableUnknown84% confidence
Washington University/Gateway zonisamide acute noise-induced hearing loss studiesStatus caveat
Sponsor / Institution: Institution-led study · Phase 2 · Discontinued
Small MoleculePhase 2Discontinued84% confidence
Colorado LOOT clemastine plus engineered sound CAPD studyStatus caveat
Sponsor / Institution: Institution-led study · Phase 1/2 · Active
Small MoleculePhase 1/2Active82% confidence
Wayne State etanercept blast/noise-induced tinnitus studyStatus caveat
Sponsor / Institution: Institution-led study · Phase 2 · Active
BiologicPhase 2Active82% confidence
SNUH dexamethasone/hyaluronic-acid intratympanic delivery studyStatus caveat
Sponsor / Institution: Institution-led study · Phase 1/2 · Completed
Drug DeliveryPhase 1/2Completed76% confidence
Zonisamide and Methylprednisolone Noise-Induced Hearing Loss Prevention StudyStatus caveat
Sponsor / Institution: Institution-led study · Phase 1/2 · Discontinued
Small MoleculePhase 1/2Discontinued72% confidence